Bipolar disorder treatment for Hollywood — the diagnosis primary care misses.

RECO Integrated Psychiatry sits 35 miles north of Hollywood — a 50-minute drive up I-95 outside of rush hour. Our clinicians run the full lithium monitoring protocol (quarterly levels, TSH, creatinine, calcium), titrate lamotrigine on the two-week Stevens-Johnson-safe schedule, and use structured instruments — MDQ, HCL-32, mood charts — to distinguish bipolar II depression from unipolar. That is the diagnostic and pharmacologic depth most generalist practices serving Broward County are not staffed to deliver.

Hollywood sits 35 miles south of RECO Integrated Psychiatry’s Delray Beach clinic — a 50-minute drive up I-95 outside of rush hour, closer to an hour once Broward and southern Palm Beach traffic build. For adults living in Hollywood Beach, Emerald Hills, Hollywood Lakes, Hollywood Hills, or Oakwood, that distance is usually the reason specialist psychiatric care is worth the trip: bipolar disorder is under-diagnosed and, when caught, frequently mistreated in general practice. A wrong diagnosis of unipolar depression — followed by an SSRI without mood-stabilizer cover — is the single most common driver of avoidable decompensation in this population, and it is exactly the problem outpatient bipolar disorder treatment at RECO is built to correct.

Bipolar I, bipolar II, and bipolar spectrum: getting the diagnosis right

Bipolar I requires a manic episode — a distinct period of elevated or irritable mood with functional impairment or psychosis lasting at least seven days, or any duration requiring hospitalization. Bipolar II requires at least one hypomanic episode of four days or more plus at least one major depressive episode, without ever meeting full manic criteria. Bipolar spectrum — cyclothymia, bipolar NOS, subthreshold bipolar, and antidepressant-induced hypomania — captures presentations with clear cyclicity that fall short of DSM-5 thresholds but still respond to mood-stabilizing pharmacology.

The distinction is not academic. Bipolar I is generally treated with a mood stabilizer plus a second-generation antipsychotic, often lithium paired with quetiapine or aripiprazole. Bipolar II depression responds best to lamotrigine and quetiapine and less predictably to lithium. Bipolar spectrum presentations often require cautious antidepressant use with mood-stabilizer cover, or no antidepressant at all. RECO’s evaluation uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist-32 (HCL-32), a structured hypomania history with collateral report where available, and a mood chart covering the preceding twelve months. When the picture is genuinely ambiguous, longitudinal monitoring — not premature medication commitment — is the correct next step, and that gets stated explicitly rather than papered over.

Lithium: the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer for bipolar I disorder and the only psychiatric medication with robust randomized-trial evidence for reducing suicide-attempt rates. Its unpopularity in general practice is a monitoring problem, not an efficacy problem. Baseline workup includes TSH, creatinine and eGFR, serum calcium, CBC, and pregnancy testing where indicated. Target serum levels are 0.6-1.0 mEq/L for maintenance and 0.8-1.2 mEq/L during acute mania, drawn 12 hours post-dose. Quarterly levels are standard through the first year; twice-yearly thereafter for stable patients.

Ongoing surveillance covers weight, thyroid function, renal function, and — in patients on ACE inhibitors, thiazides, or NSAIDs — drug interactions that predictably raise lithium levels. Hypothyroidism and mild, non-progressive elevations in creatinine are common and typically managed rather than triggering discontinuation. RECO’s protocol builds the labs, the level draws, and the phone follow-up into the schedule so it happens without the patient having to chase it. For the majority of patients who tolerate lithium, the outcome data justify the monitoring burden.

Second-generation antipsychotics and where they fit

Several second-generation antipsychotics carry FDA approval in specific bipolar indications. Quetiapine is approved for bipolar depression, acute mania, and maintenance, which makes it one of the most flexible tools in the class. Lurasidone is approved for bipolar depression with a favorable metabolic profile. Aripiprazole covers acute mania and maintenance, including long-acting injectable formulations for patients with adherence concerns. Olanzapine and olanzapine-fluoxetine combination are effective for bipolar depression and mania but carry the highest metabolic burden. Risperidone and cariprazine are appropriate for mania and mixed states.

Choice is driven by the phase being treated, prior response history, tolerability, and metabolic risk. Baseline and ongoing monitoring follows the standard schedule: weight, BMI, waist circumference, fasting glucose or HbA1c, lipid panel, and blood pressure at baseline, 12 weeks, and annually. Prolactin and treatment-emergent movement disorders are assessed clinically. Patients starting one of these medications from Hollywood should expect a follow-up visit within two to four weeks, with labs drawn before that appointment so the numbers, not impressions, drive the next decision.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence base for bipolar II depression and for bipolar maintenance when depression is the predominant pole. Titration is deliberately slow — 25 mg daily for two weeks, 50 mg daily for two weeks, 100 mg for one week, then 200 mg — because rapid titration is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients are counseled to stop the drug and seek urgent evaluation for any rash during the titration window. Once at maintenance dose, lamotrigine is generally well-tolerated and does not require serum-level monitoring.

Valproate (divalproex sodium) is effective for acute mania, mixed states, and rapid cycling. Baseline labs include LFTs, CBC with platelets, and pregnancy testing; the drug is teratogenic and carries a black-box warning for neural tube defects, so contraception counseling is standard for patients of childbearing potential. Target trough serum levels are 50-125 mcg/mL. Carbamazepine is a second-line option with a significant drug-interaction load through CYP450 induction, and oxcarbazepine is used off-label with a cleaner interaction profile. Each anticonvulsant has a defined monitoring protocol, and RECO runs each of them.

Psychotherapy modalities with evidence in bipolar disorder

Medication is the load-bearing intervention in bipolar disorder, but the psychotherapies with the strongest evidence — interpersonal and social rhythm therapy (IPSRT), family-focused therapy, and CBT adapted for bipolar — meaningfully reduce recurrence rates when added to pharmacotherapy. IPSRT targets the sleep-wake and daily-routine disruptions that reliably precede manic and depressive episodes. Family-focused therapy educates household members on prodromal signs and communication patterns and has trial data supporting shorter and less severe recurrences.

RECO coordinates directly with community therapists trained in these modalities for Hollywood clients who prefer to keep their existing therapy relationship, and can also connect patients with therapists inside the RECO network. What is not appropriate — and what patients often arrive on — is generic supportive therapy without a bipolar-specific framework.

What to expect on your first visit, and insurance from Hollywood

The initial evaluation runs 60-90 minutes with a board-certified psychiatrist or psychiatric mental-health nurse practitioner. It covers a structured psychiatric history, formal MDQ and HCL-32 screening, a chronological mood timeline, family psychiatric history, prior medication trials, substance use, sleep, and relevant medical history. PHQ-9 and GAD-7 are administered for current-state severity. Baseline labs — CMP, TSH, CBC, HbA1c, lipids, and pregnancy testing where indicated — are ordered so mood-stabilizer options are on the table at the second visit.

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Outpatient psychiatric medication management is a standard covered benefit under federal mental-health parity law. Most Hollywood clients complete the initial evaluation and first one or two follow-ups in person, then transition to telepsychiatry for routine maintenance visits — a schedule that fits the 50-minute drive without making distance a barrier to consistent care.

Serving residents of: Hollywood Beach, Emerald Hills, Hollywood Lakes, Hollywood Hills, Oakwood.